AFFiRiS AG

Novel disease-modifying therapies for neurodegenerative diseases.
From brains for brains. From us for you.

[AFFiRiS AG @AFFiRiSAG]

Today, AFFiRiS announced a license agreement with Frontier Biotechnologies Inc to develop its active immunotherapy targeting #PCSK9 for the treatment of #hypercholesterolemia in #GreaterChina: https://t.co/wCDovGg69u

[AFFiRiS AG @AFFiRiSAG]

AFFiRiS announced today that @AC_Immune_SA acquires its Specific Active Immunotherapy anti-alpha-synuclein programs that target #neurodegenerativediseases caused by misfolded forms of human self-proteins.: https://t.co/wCDovGg69u

[AFFiRiS AG @AFFiRiSAG]

AFFiRiS’ immunotherapy candidates showed promising results in a phase 1 study in the cardiovascular disease indication #hypercholesterolemia: Active immunization was safe, well-tolerated, immunogenic, and led to a significant decrease in #LDLc: https://t.co/wCDovGg69u

[AFFiRiS AG @AFFiRiSAG]

Positive preclinical in vivo results with our mAB C6-17 to treat #Huntingtonsdisease at the Annual Huntington's Disease Therapeutics Conference: Our antibody showed reduced mtHTT levels and displaying improved motor performance in the treated animals. PR: https://t.co/4RKmLG7CJ2

[The Science of Parkinson's @ScienceofPD]

An analyze the therapeutic efficacy of @AFFiRiSAG's PD03 (a new AFFITOPE® immunotherapy approach) either alone or in combination with MODAG's Anle138b in a α-synucleinopathy PLP-α-syn mouse model
https://t.co/gR4OT8th7Y

[AFFiRiS AG @AFFiRiSAG]

Assessing Immunotherapies Targeting α-Synuclein in Parkinson Disease https://t.co/LPODZ5gjlw via @AJMC_Journal #Affiris #PD01a #PD03A

[AFFiRiS AG @AFFiRiSAG]

We announce the presentation of #PD01 data in #PD at the MDS Virtual Congress. Dr. Staffler, CTO, “Long term safety and immunogenicity of the aSyn active immunotherapeutic PD01A in patients with Parkinson’s disease: a Phase I study series” More info here: https://t.co/4RKmLG7CJ2

[AFFiRiS AG @AFFiRiSAG]

@ScienceofPD We published today a PressRelease 😀 https://t.co/4RKmLG7CJ2 😃

[AFFiRiS AG @AFFiRiSAG]

Positive results of our Phase 1 trial in #MSA have been published in the peer-reviewed @MDJ_Journal. Immunization with #AFFITOPEs PD01A and PD03A was safe, well tolerated and triggered a rapid and long-lasting #antibodyresponse against the #aSynprotein https://t.co/4RKmLG7CJ2

[MDS @movedisorder]

Disease-modifying therapies can offer a new perspective on Parkinson’s disease treatment. This session will include discussion of lysosome-targeted therapies, intervention using the immune system, and anti-body-based therapies. #MDSCongress https://t.co/cFr4IJCAxP

[AFFiRiS AG @AFFiRiSAG]

Do you remember when you joined Twitter? I do! #MyTwitterAnniversary 😀😊🥰

[AFFiRiS AG @AFFiRiSAG]

"Konzept scheint zu funktionieren: Parkinson-Impfstoff erstmals in Phase-I-Studie untersucht" https://t.co/RHx7co8U7c #DeutschenApotherkerZeitung

[AFFiRiS AG @AFFiRiSAG]

Active Immunotherapy Shows Safety, Tolerability in Parkinson’s @physicianswkly https://t.co/WmJEiNFrDW

[AFFiRiS AG @AFFiRiSAG]

.@AFFiRiSAG is featured in the @EuroamSonntag article „Immune response to Parkinson's”. @CarbonJulie, editor, writes about the positive results of AFFiRiS’ phase 1 and how #PD01 could be a promising therapy against #Parkinsonsdisease: https://t.co/bTRekS4Npc

[AFFiRiS AG @AFFiRiSAG]

Parkinson: Eine Impfung weckt Hoffnungen https://t.co/6hnwKCVmMg @gesundheitcom

[AFFiRiS AG @AFFiRiSAG]

Passi avanti verso un vaccino per il #Parkinson https://t.co/Es8INXLPtP via @CorrNazionale

[MIG Fonds @MIGFonds]

Positive Ergebnisse der Phase 1-Studie vom MIG Fonds Portfoliounternehmen @AFFiRiSAG mit dem Wirkstoff PD01 zur Behandlung von Parkinson-Patienten!
https://t.co/r46KiqTFNv

#MIGFonds #Affiris #HMW #biotech #parkinson

[Fundación_Degén @Fundacion_Degen]

¡SE PUBLICAN LOS PRIMEROS RESULTADOS DE LA VACUNA PARA FRENAR EL #PARKINSON!

Se administraron 6 dosis en 21 pacientes a lo largo de más de 3 años. Es segura y produce anticuerpos contra la alfa-sinucleína.

https://t.co/OOWUPjuvng

[AFFiRiS AG @AFFiRiSAG]

Da Vienna i primi dati incoraggianti di un #vaccino contro la malattia di #Parkinson in stadio iniziale #PD01 https://t.co/FIxyWB4jJP @PharmaStar

[AFFiRiS AG @AFFiRiSAG]

.@TheLancetNeuro published the positive results of the Phase 1 with our #PD01A in #Parkinsonsdisease patients. #PD01 is safe and well-tolerated and led to a specific antibody response, and memory effect, resulting in a reduction in oligomeric aSyn protein https://t.co/akI9aOJmpb